COMMUNIQUÉS West-GlobeNewswire

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
22/04/2026
HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous [...]
Altimmune Announces Proposed Underwritten Public Offering of Securities
22/04/2026
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced it has [...]
Dentsply Sirona to Host First Quarter 2026 Conference Call on May 5
22/04/2026
CHARLOTTE, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on [...]
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
22/04/2026
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the [...]
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
22/04/2026
ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
22/04/2026
ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The [...]
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
22/04/2026
BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines BBO-11818 demonstrates robust [...]
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
22/04/2026
BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business [...]
Inventiva renforce son équipe de direction à l’approche des résultats de Phase 3 du lanifibranor
22/04/2026
Le recrutement d’un Directeur Financier, d’une Directrice Juridique et d’une Directrice des Ressources Humaines reflète le renforcement de l’organisation d’Inventiva à mesure que la société se prépare à une éventuelle [...]
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
22/04/2026
Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva’s organizational build-out as it advances toward potential commercialization. Axel-Sven Malkomes joins as Chief [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
22/04/2026
Company announcement – No. 9 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April [...]
Teknova to Report First Quarter 2026 Financial Results on May 6, 2026
22/04/2026
HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Abivax to Present Data on Obefazimod at Digestive Disease Week®
22/04/2026
Abivax to Present Data on Obefazimod at Digestive Disease Week ® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical Anti-Fibrotic Models [...]
PetMeds announces strategic partnership with Rural King to launch pet pharmacy offering across retail and digital channels
22/04/2026
Collaboration expands access to affordable pet medications for rural communities nationwide DELRAY BEACH, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., doing business as PetMeds and parent company of [...]
TOMI Environmental Solutions Scales Automation with SteraMist iHP Robot Upgrade; Targets Fast Growing Robotaxi Market
22/04/2026
Pairing Decontamination Versatility with Domestic Lithium Power to Meet the Global Demand for High-Performance Automated Disinfection FREDERICK, Md., April 22, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc [...]
SkinHealth Systems Inc. Appoints Three New Independent Directors to Board
22/04/2026
Kenneth Tripp, Dr. Sachin Shridharani, and E. Scott Beattie bring deep expertise in medical devices, aesthetic medicine, and global consumer brands LONG BEACH, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- SkinHealth [...]
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22/04/2026
CHASKA, Minn., April 22, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
22/04/2026
Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027 LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- [...]
Coloplast A/S - H1 2025/26 Earnings Release - Invitation for conference call on 12 May 2026 at 11:00 CEST
22/04/2026
Tuesday, 12 May 2026 at 11:00 - 12:00 CEST In connection with the publication of Coloplast’s interim financial results for H1 2025/26, to be released same day around 07:30 CEST, Coloplast will host a conference call to [...]

Pages